These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12122922)

  • 21. The intravenous ketamine test: a predictive response tool for oral dextromethorphan treatment in neuropathic pain.
    Cohen SP; Chang AS; Larkin T; Mao J
    Anesth Analg; 2004 Dec; 99(6):1753-1759. PubMed ID: 15562066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to S.T. Meller: Ketamine: relief from chronic pain through actions at the NMDA receptor.
    Eide PK; Stubhaug A; Breivik H; Oye I
    Pain; 1997 Aug; 72(1-2):289-91. PubMed ID: 9272819
    [No Abstract]   [Full Text] [Related]  

  • 23. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?
    Wiesenfeld-Hallin Z
    Drugs; 1998 Jan; 55(1):1-4. PubMed ID: 9463786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial.
    Noppers I; Niesters M; Swartjes M; Bauer M; Aarts L; Geleijnse N; Mooren R; Dahan A; Sarton E
    Eur J Pain; 2011 Oct; 15(9):942-9. PubMed ID: 21482474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NMDA receptor antagonists and pain relief: A meta-analysis of experimental trials.
    Thompson T; Whiter F; Gallop K; Veronese N; Solmi M; Newton P; Stubbs B
    Neurology; 2019 Apr; 92(14):e1652-e1662. PubMed ID: 30842296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonselective and NR2B-selective N-methyl-D-aspartic acid receptor antagonists produce antinociception and long-term relief of allodynia in acute and neuropathic pain.
    Swartjes M; Morariu A; Niesters M; Aarts L; Dahan A
    Anesthesiology; 2011 Jul; 115(1):165-74. PubMed ID: 21606828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
    Krystal JH
    Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
    [No Abstract]   [Full Text] [Related]  

  • 29. Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain.
    Baker AK; Hoffmann VL; Meert TF
    Pharmacol Biochem Behav; 2002 Dec; 74(1):73-86. PubMed ID: 12376154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements.
    Helmy SA; Bali A
    Anesth Analg; 2001 Mar; 92(3):739-44. PubMed ID: 11226111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade.
    Eide PK; Stubhaug A
    Neurosurgery; 1997 Aug; 41(2):505-8. PubMed ID: 9257324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats.
    Sawynok J; Reid A
    Pain; 2003 Mar; 102(1-2):179-86. PubMed ID: 12620609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of a multicenter randomized clinical trial with memantine and dextromethorphan in ketamine-responder patients.
    Pickering G; Pereira B; Morel V; Tiberghien F; Martin E; Marcaillou F; Picard P; Delage N; de Montgazon G; Sorel M; Roux D; Dubray C
    Contemp Clin Trials; 2014 Jul; 38(2):314-20. PubMed ID: 24948402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [NMDA receptor antagonists: a new treatment for neuropathic pain].
    Pud D; Eisenberg E
    Harefuah; 1999 Apr; 136(7):564-7. PubMed ID: 15532603
    [No Abstract]   [Full Text] [Related]  

  • 36. NMDA receptor antagonists for the treatment of neuropathic pain.
    Collins S; Sigtermans MJ; Dahan A; Zuurmond WW; Perez RS
    Pain Med; 2010 Nov; 11(11):1726-42. PubMed ID: 21044263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
    Hashimoto K
    Psychopharmacology (Berl); 2014 Oct; 231(20):4081-2. PubMed ID: 25189793
    [No Abstract]   [Full Text] [Related]  

  • 38. Four years' treatment with ketamine and a trial of dextromethorphan in a patient with severe post-herpetic neuralgia.
    Klepstad P; Borchgrevink PC
    Acta Anaesthesiol Scand; 1997 Mar; 41(3):422-6. PubMed ID: 9113190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NMDA receptor blockade prevents nitroglycerin-induced headaches.
    Roffey P; Mikhail M; Thangathurai D
    Headache; 2001; 41(7):733. PubMed ID: 11554966
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of N-methyl-D-aspartate antagonists on different measures of motion sickness in cats.
    Lucot JB
    Brain Res Bull; 1998 Nov; 47(5):407-11. PubMed ID: 10052568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.